The 6-month blinded interim analysis of a Phase 1b Alzheimer's trial showed no ARIA-E, a low total ARIA rate, and favorable safety across all genotypes. Both plasma pTau217 and CSF MTBR-tau243 biomarkers declined, suggesting early target engagement and potential disease modification. Topline 12-month results are expected in Q1 2027.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.